PADCEV ® (enfortumab vedotin) in combination with pembrolizumab approved by Health Canada to treat advanced...

Merck & Co. bags one Kelun ADC for $37.5M, boots out another asset as pipeline...

Denmark’s Adcendo signs $1B biobuck deal for Multitude’s anti-TF ADC

FDA greenlights BioNTech/Medilink’s cancer trial at lower dose after deaths

GSK5764227 Gains FDA Breakthrough Therapy Designation in ES-SCLC

ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2...

ENHERTU® Type II Variation Application Validated by EMA for Patients with HER2 Low or HER2...